Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)

42.01 +0.33 (+0.79%)
Streaming Delayed Price Updated: 12:40 PM EDT, Oct 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crinetics Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Biotech Stock Crinetics Pharmaceuticals Positioned For Success In Chronic Endocrine Disorder Treatment, Says Analyst
Oppenheimer initiated coverage on Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) with an Outperform rating  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2023
 
Via Benzinga
9 Analysts Have This to Say About Crinetics Pharmaceuticals
 
Via Benzinga
Analyst Expectations for Crinetics Pharmaceuticals's Future
 
Via Benzinga
Where Crinetics Pharmaceuticals Stands With Analysts
 
Via Benzinga
The Latest Analyst Ratings for Crinetics Pharmaceuticals
 
Via Benzinga
Crinetics Pharmaceuticals's Return On Capital Employed Overview
 
Via Benzinga
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics to Highlight Broad Pipeline at ENDO 2023
Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for Entrepreneurship 
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
 
Via Benzinga
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
Topline results for PATHFNDR-1 study expected in Q3 2023 
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals's Return On Capital Employed Overview
Benzinga Pro data, Crinetics Pharmaceuticals (NASDAQ:CRNX) reported Q2 sales of $439 thousand. Earnings fell to a loss of $42.38 million, resulting in a 22.38% decrease from last quarter. 
Via Benzinga
Crinetics Pharmaceuticals: Q2 Earnings Insights
  Crinetics Pharmaceuticals (NASDAQ:CRNX) reported its Q2 earnings results on Friday, August 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Crinetics Pharmaceuticals Announces Positive Top-line Results From CRN04894 Early-Stage Trial
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) revealed positive topline results from a first-in-human Phase 1 clinical study of CRN04894 for the treatment of patients with Cushing's disease. 
Via Benzinga
88 Biggest Movers From Yesterday
Gainers The Very Good Food Company Inc. (NASDAQ: VGFC) shares jumped 118.2% to close at $0.2950 on Wednesday as the company announced it increased retail distribution across Canada with Loblaw... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.